Dual Mechanism of Daraxonrasib in RAS(ON) Inhibition Enhances Anti-Tumor Immunity

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Abstract PR009: The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agentsEarly-Phase Clinical Trial · 2026
2. 2Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcomaOriginal Research · 2026
3. 3Abstract A118: Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC2025 · 1 citations
4. 4Abstract 6782: Discovery of a new class of mutant-targeted catalytic RAS(ON) inhibitors with retained antitumor activity in setting of emergent resistance due to elevated RAS fluxOriginal Research · 2026
5. 5Abstract 1884: Molecular determinants of sensitivity and resistance to the pan-RAS(ON) inhibitor daraxonrasib(RMC-6236) across KRAS-mutant patient-derived models.Original Research · 2026